|
Cardiovascular medicine
Citations 1331-1340 of 25897 total displayed.
|
Past content
(since Oct 1840):
|
-
- Endgames
- Randomised controlled trials: evaluating and communicating treatment effects
- Philip Sedgwick and Katherine Joekes
-
BMJ 2014;348:g1905, doi: 10.1136/bmj.g1905,
-
[Extract]
[Full text]
[PDF]
-
- Practice
- Thoracic Trauma
- Andrew Blyth
-
BMJ 2014;348:bmj.g1137, doi: 10.1136/bmj.g1137,
-
[Extract]
[Full text]
-
- Practice
- Hypovolaemic Shock
- Jerry P. Nolan and Rick Pullinger
-
BMJ 2014;348:bmj.g1139, doi: 10.1136/bmj.g1139,
-
[Extract]
[Full text]
-
- Letters
- Differentiating between "no proof of difference" and "proof of no difference" for new oral anticoagulants
- Andrea Messori, Valeria Fadda, Roberta Gatto, Dario Maratea, and Sabrina Trippoli
-
BMJ 2014;348:g1955, doi: 10.1136/bmj.g1955,
-
[Extract]
[Full text]
[PDF]
-
- Editorials
- Removing the hype from hypertension
- Matthew J Shun-Shin, James P Howard, and Darrel P Francis
-
BMJ 2014;348:g1937, doi: 10.1136/bmj.g1937,
-
[Extract]
[Full text]
[PDF]
-
- Editor's choice
- Who are we treating?
- Fiona Godlee
-
BMJ 2014;348:g1954, doi: 10.1136/bmj.g1954,
-
[Extract]
[Full text]
[PDF]
-
- Letters
- Post-approval adverse events of new and old anticoagulants
- Keith B Hoffman, Andrea Demakas, Colin B Erdman, and Mo Dimbil
-
BMJ 2014;348:g1859, doi: 10.1136/bmj.g1859,
-
[Extract]
[Full text]
[PDF]
-
- Letters
- Safety of new oral anticoagulants in high risk patients
- Stephen Dalgleish
-
BMJ 2014;348:g1861, doi: 10.1136/bmj.g1861,
-
[Extract]
[Full text]
[PDF]
-
- Analysis
- Setting performance targets in pay for performance programmes: what can we learn from QOF?
- Tim Doran, Evangelos Kontopantelis, David Reeves, Matthew Sutton, and Andrew M Ryan
-
BMJ 2014;348:g1595, doi: 10.1136/bmj.g1595,
-
[Extract]
[Full text]
[PDF]
-
- Feature
- Primary care team of the year: saving money and improving care
- Chris Mahony
-
BMJ 2014;348:g1753, doi: 10.1136/bmj.g1753,
-
[Extract]
[Full text]
[PDF]
|